

Press release, September 30, 2008

New share issue in Biovitrum AB (publ)

In accordance with Biovitrum stock option program 2006:2 TO3 2006/2008, 250 502 new shares have been issued at the price SEK 59.00 per share, resulting in Biovitrum being provided funds of a total of SEK 14 779 618.00. No stock options remain in the stock option program 2006:2 TO3 2006/2008.

After the share issue the outstanding number of shares in Biovitrum is 46 015 624.

For more information please contact:

Biovitrum

Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com

About Biovitrum

Biovitrum is a pharmaceutical company with operations in Sweden and in the UK. The company markets a range of specialist pharmaceuticals primarily in the Nordic countries. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities include development and production of biotechnology therapeutics, as well as small molecule discovery and development. With revenues of approximately SEK 1.3 billion and around 500 employees, Biovitrum is a significant European specialty pharmaceutical player. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com.